Amphastar Pharmaceuticals, Inc. (AMPH)
NASDAQ: AMPH · Real-Time Price · USD
50.53
-0.25 (-0.49%)
Oct 31, 2024, 4:00 PM EDT - Market closed
Amphastar Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Operating Revenue | 644.52 | 593.24 | 498.99 | 437.77 | 349.85 | 322.36 | Upgrade
|
Other Revenue | 68.37 | 51.16 | - | - | - | - | Upgrade
|
Revenue | 712.89 | 644.4 | 498.99 | 437.77 | 349.85 | 322.36 | Upgrade
|
Revenue Growth (YoY) | 31.80% | 29.14% | 13.98% | 25.13% | 8.53% | 9.40% | Upgrade
|
Cost of Revenue | 320.38 | 290.57 | 250.13 | 238.03 | 206.51 | 190.43 | Upgrade
|
Gross Profit | 392.51 | 353.82 | 248.86 | 199.74 | 143.34 | 131.92 | Upgrade
|
Selling, General & Admin | 88.15 | 80.39 | 66.59 | 67.12 | 62.86 | 63.11 | Upgrade
|
Research & Development | 71.78 | 73.74 | 74.77 | 60.93 | 67.23 | 68.85 | Upgrade
|
Operating Expenses | 159.92 | 154.13 | 141.36 | 128.05 | 130.09 | 131.96 | Upgrade
|
Operating Income | 232.59 | 199.69 | 107.5 | 71.69 | 13.25 | -0.04 | Upgrade
|
Interest Expense | -32.38 | -27.16 | -1.85 | -0.89 | -0.37 | -0.12 | Upgrade
|
Interest & Investment Income | 9.4 | 5.46 | 1.32 | 0.6 | 0.64 | 1 | Upgrade
|
Earnings From Equity Investments | -1.47 | -1.98 | -1.18 | -0.21 | - | - | Upgrade
|
Other Non Operating Income (Expenses) | -3.8 | -3.93 | 3.67 | 13.54 | 6.22 | -0.51 | Upgrade
|
EBT Excluding Unusual Items | 204.33 | 172.08 | 109.46 | 84.73 | 19.74 | 0.33 | Upgrade
|
Asset Writedown | -2.7 | -2.7 | - | - | - | - | Upgrade
|
Legal Settlements | - | - | 5.4 | 1 | -12.8 | 59.9 | Upgrade
|
Other Unusual Items | - | - | - | -1.8 | -2.3 | - | Upgrade
|
Pretax Income | 201.63 | 169.38 | 114.86 | 83.93 | 4.64 | 60.23 | Upgrade
|
Income Tax Expense | 35.12 | 31.83 | 23.48 | 20.63 | 3.54 | 13.72 | Upgrade
|
Earnings From Continuing Operations | 166.52 | 137.55 | 91.39 | 63.3 | 1.1 | 46.51 | Upgrade
|
Minority Interest in Earnings | - | - | - | -1.19 | 0.31 | 2.43 | Upgrade
|
Net Income | 166.52 | 137.55 | 91.39 | 62.12 | 1.4 | 48.94 | Upgrade
|
Net Income to Common | 166.52 | 137.55 | 91.39 | 62.12 | 1.4 | 48.94 | Upgrade
|
Net Income Growth | 63.34% | 50.51% | 47.12% | 4327.37% | -97.13% | - | Upgrade
|
Shares Outstanding (Basic) | 48 | 48 | 49 | 48 | 47 | 47 | Upgrade
|
Shares Outstanding (Diluted) | 53 | 53 | 52 | 50 | 49 | 50 | Upgrade
|
Shares Change (YoY) | 1.15% | 1.09% | 5.31% | 1.34% | -1.57% | 7.57% | Upgrade
|
EPS (Basic) | 3.44 | 2.85 | 1.88 | 1.30 | 0.03 | 1.04 | Upgrade
|
EPS (Diluted) | 3.15 | 2.60 | 1.74 | 1.25 | 0.03 | 0.98 | Upgrade
|
EPS Growth | 62.07% | 49.43% | 39.20% | 4090.97% | -96.96% | - | Upgrade
|
Free Cash Flow | 178.13 | 145.34 | 65.15 | 70.54 | 23.41 | 0.21 | Upgrade
|
Free Cash Flow Per Share | 3.36 | 2.74 | 1.24 | 1.42 | 0.48 | 0.00 | Upgrade
|
Gross Margin | 55.06% | 54.91% | 49.87% | 45.63% | 40.97% | 40.92% | Upgrade
|
Operating Margin | 32.63% | 30.99% | 21.54% | 16.38% | 3.79% | -0.01% | Upgrade
|
Profit Margin | 23.36% | 21.34% | 18.31% | 14.19% | 0.40% | 15.18% | Upgrade
|
Free Cash Flow Margin | 24.99% | 22.55% | 13.06% | 16.11% | 6.69% | 0.06% | Upgrade
|
EBITDA | 284.16 | 237.72 | 132.27 | 94.95 | 34.78 | 18.07 | Upgrade
|
EBITDA Margin | 39.86% | 36.89% | 26.51% | 21.69% | 9.94% | 5.61% | Upgrade
|
D&A For EBITDA | 51.57 | 38.04 | 24.77 | 23.27 | 21.53 | 18.11 | Upgrade
|
EBIT | 232.59 | 199.69 | 107.5 | 71.69 | 13.25 | -0.04 | Upgrade
|
EBIT Margin | 32.63% | 30.99% | 21.54% | 16.38% | 3.79% | -0.01% | Upgrade
|
Effective Tax Rate | 17.42% | 18.79% | 20.44% | 24.58% | 76.34% | 22.79% | Upgrade
|
Revenue as Reported | 712.89 | 644.4 | 498.99 | 437.77 | - | - | Upgrade
|
Advertising Expenses | - | 10.4 | 8.7 | 8.1 | 5.8 | 4.3 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.